Pancreatic Cancer Research

ResearcherUniversity of CologneActive in the last 2 years

Dirk Waldschmidt

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110666041. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 2, last author 2)
Trials
1
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 3 papers, 1 trial · 2022: 1 paper · 2023: none · 2024: 6 papers · 2025: 1 paper · 2026: 2 papers

Papers 21

  1. Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216). Co-author DOI 10.1038/s41416-025-03188-x↗
  2. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  3. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  4. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
  5. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
  6. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  7. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  8. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  9. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Co-author DOI 10.1016/j.tranon.2024.102044↗
  10. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  11. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  12. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… First author DOI 10.1016/j.ejca.2020.12.029↗
  13. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  14. [Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial]. Last author DOI 10.1055/a-1071-8177↗
  15. Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. Co-author DOI 10.1159/000504697↗
  16. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional mul… Last author DOI 10.1186/s12885-020-6636-7↗
  17. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". Co-author DOI 10.1186/s12885-019-6448-9↗
  18. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  19. Copy-number variation and protein expression of DOT1L in pancreatic adenocarcinoma as a potential drug target. First author DOI 10.3892/mco.2017.1194↗
  20. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Co-author DOI 10.3109/0284186x.2015.1034877↗
  21. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of … Co-author DOI 10.1136/gutjnl-2012-302759↗

Trials 1

  1. Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas Study director NCT04617457↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefan Hubert Boeck · 12 shared papers, 2013–2026 · strength 1.61
  2. Volker Heinemann · 12 shared papers, 2013–2024 · strength 1.42
  3. Jens Thomas Siveke · 6 shared papers, 2021–2024 · strength 0.86
  4. Christoph Benedikt Westphalen · 6 shared papers, 2020–2024 · strength 0.83
  5. Anke Reinacher‐Schick · 5 shared papers, 2021–2026 · strength 0.83
  6. Thomas Jens Ettrich · 5 shared papers, 2021–2026 · strength 0.74
  7. Michael Haas · 5 shared papers, 2015–2024 · strength 0.65
  8. Uwe Pelzer · 5 shared papers, 2017–2024 · strength 0.58
  9. Ingo Hartlapp · 4 shared papers, 2021–2024 · strength 0.53
  10. Frank Kullmann · 4 shared papers, 2021–2024 · strength 0.53
  11. Uwe M. Martens · 4 shared papers, 2021–2024 · strength 0.53
  12. Volker Kunzmann · 4 shared papers, 2021–2024 · strength 0.53
  13. Hana Algül · 4 shared papers, 2021–2024 · strength 0.53
  14. Lena Weiss · 3 shared papers, 2024 · strength 0.52
  15. Klara Dorman · 3 shared papers, 2024 · strength 0.52
  16. Michael Ståhl · 4 shared papers, 2021–2024 · strength 0.51
  17. Michael B. Ghadimi · 3 shared papers, 2017–2026 · strength 0.46
  18. Robert Grützmann · 3 shared papers, 2017–2026 · strength 0.46
  19. Helmut Oettle · 3 shared papers, 2017–2026 · strength 0.46
  20. Brigitte Kimmel · 3 shared papers, 2022–2024 · strength 0.44
  21. Friedrich Anger · 3 shared papers, 2022–2024 · strength 0.44
  22. Florian Gebauer · 1 shared trial, 2021 · strength 0.42
  23. Sabine Semrau · 2 shared papers, 2025–2026 · strength 0.40
  24. Rainer Fietkau · 2 shared papers, 2025–2026 · strength 0.40
  25. Andrea Tannapfel · 2 shared papers, 2025–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.